Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.
Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.
Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.
For more information, please visit www.karyopharm.com.
Karyopharm Therapeutics reported Q2 2021 results, highlighting a 21% increase in XPOVIO revenue, reaching $20.2 million. The company aims for FDA approval for XPOVIO in endometrial cancer by year-end. Despite a net loss of $53.6 million or $0.71 per share, the management noted a strong cash position of $239.3 million as of June 30, 2021, sufficient to fund operations into mid-2023. R&D expenses dropped 20% year-over-year, while SG&A costs rose 18%.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation by CEO Richard Paulson in two virtual investor conferences. The Wedbush PacGrow Healthcare Virtual Conference will take place on August 10, 2021, at 8:35 AM ET. The Canaccord Genuity 41st Annual Growth Conference is set for August 12, 2021, at 3:30 PM ET. Live webcasts will be available on the company's website, with replays archived for 30 days. Karyopharm focuses on pioneering cancer therapies and is known for its lead drug, XPOVIO®.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on August 2, 2021, that the Compensation Committee granted stock options to purchase 74,600 shares of common stock to 11 new employees. The options, with an exercise price of $8.33 per share, are part of the company's strategy to incentivize new hires. Each option vests over four years, with specific terms related to employment status and a potential 'change in control event.'
Karyopharm is focused on developing novel cancer therapies, including the approved drug XPOVIO (selinexor).
Karyopharm Therapeutics (Nasdaq: KPTI) will report its second quarter 2021 financial results on August 5, 2021. A conference call hosted by the management team is scheduled for 8:30 a.m. ET on the same day to discuss the results and provide company updates. Karyopharm specializes in developing novel cancer therapies, focusing on SINE compounds that inhibit the nuclear export protein XPO1, with its lead product XPOVIO already approved in the U.S. for various malignancies.
Karyopharm Therapeutics (NASDAQ: KPTI) announced the start of patient dosing in two new Phase 2 and 1/2 clinical studies for XPOVIO® (selinexor) in advanced melanoma and treatment-naïve myelofibrosis. The Phase 2 study will assess XPOVIO combined with Keytruda® in patients resistant to prior treatments. The Phase 1/2 study will evaluate XPOVIO with Jakafi® in treatment-naïve myelofibrosis patients. These studies follow promising preclinical and earlier clinical data, highlighting the ongoing need for innovative cancer therapies.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that it granted stock options to newly hired employees, including 125,000 shares to Ms. Sohanya Cheng, Senior VP, Sales and Commercial Operations, as an inducement for joining the company. The options have an exercise price of $10.32 per share, matching the closing price on June 30, 2021. Options vest over four years and may vest earlier upon termination without cause or a change in control event. This move aligns with Nasdaq Listing Rule 5635(c)(4) on compensatory stock option grants.
Karyopharm Therapeutics (NASDAQ: KPTI) announced an expanded royalty agreement with HealthCare Royalty Management for up to $100 million in financing to support the development of XPOVIO® (selinexor) and other programs. The initial $60 million has been received, with potential for two additional $20 million payments tied to milestones. XPOVIO is approved for multiple hematologic malignancies in the U.S. and has conditional marketing in Europe for multiple myeloma. Karyopharm expects the financing to sustain operations into mid-2023.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the selection of nine abstracts for virtual presentation at the European Hematology Association (EHA) 2021 Virtual Congress from June 9-17, 2021. The abstracts showcase clinical data on XPOVIO® (selinexor), including subgroup analyses from the Phase 3 BOSTON study and updated data from the Phase 1b/2 STOMP study. Notably, an oral presentation will focus on the combination treatment achieving a 78% overall response rate among multiple myeloma patients. This highlights Karyopharm's ongoing commitment to advancing cancer therapies.
Karyopharm Therapeutics (KPTI) reported positive Phase I/II results for eltanexor, a treatment for hypomethylating agent refractory myelodysplastic syndrome (MDS), during the ASCO Annual Meeting. Out of 15 evaluable patients, 47% achieved marrow complete response (mCR), and the total disease control rate was 80%. Notably, patients with mCR had a median overall survival (mOS) of 11.86 months, compared to 8.67 months for those without mCR. Eltanexor may offer a more tolerable option compared to first-generation inhibitors, with trials ongoing in Asia Pacific markets.
Karyopharm Therapeutics (Nasdaq: KPTI) announced significant management changes aimed at enhancing its commercial operations, including the appointment of Sohanya Cheng as Senior Vice President of Sales and Commercial Operations. Payman Darouian will oversee marketing for the company's lead product, XPOVIO (selinexor), while former executives John Demaree and Perry Monaco will leave to pursue other opportunities. Cheng, with 17 years in biopharmaceuticals, previously led marketing at Arrowhead Pharmaceuticals and has extensive oncology experience, contributing to the company's strategy for multiple myeloma and lymphoma.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics' main focus?
What is XPOVIO® (selinexor)?
What recent achievements has Karyopharm reported?
Who are Karyopharm's global partners?
What are Karyopharm's financial highlights?
What are the key indications for XPOVIO?
What is the significance of Karyopharm's research on nuclear export proteins?
How does Karyopharm support clinical trials and research?
What are the safety considerations for XPOVIO?
How can I get more information about Karyopharm's products or clinical trials?
